BRD4 and lymphoma: Recent studies show that small molecule modulation of the acetyl-lysine binding activity of BRD proteins such as the bromodomain and extra-terminal domain (BET) family protein BRD4 dictates gene transcription outcome in disease models such as lymphoma, ischemia, and HIV-associated kidney disease, indicating BRD4 protein as an attractive drug target for pathologies including cancer and inflammation [9].